Semantic Scholar uses AI to extract papers important to this topic.
Doxorubicin is believed to cause dose-dependent cardiotoxicity through redox cycling and the generation of reactive oxygen… Expand BACKGROUND
Sunitinib, a multitargeted tyrosine-kinase inhibitor, which is approved by both US and European Commission regulatory… Expand Cancer therapy has progressed remarkably in recent years. In no area has this been more apparent than in the development of… Expand We assessed cardiovascular disease (CVD) incidence in 1474 survivors of Hodgkin lymphoma (HL) younger than 41 years at treatment… Expand Imatinib mesylate (Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous… Expand The clinical use of anthracyclines like doxorubicin and daunorubicin can be viewed as a sort of double-edged sword. On the one… Expand BACKGROUND
The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30… Expand Anthracyclines, such as doxorubicin and daunorubicin, are highly effective anticancer agents that produce a well‐described but… Expand Doxorubicin (Adriamycin) was administered by continuous infusion to reduce peak plasma levels and thus lessen cardiac toxicity… Expand The cardiotoxic effects of adriamycin were studied in 399 patients treated for far‐advanced carcimma. Forty‐five patients (11… Expand